Table 1. Clinicopathological criteria of locally advanced primary breast cancer patients who underwent neoadjuvant anthracycline-based chemotherapy.
|
Thioredoxin |
Thioredoxin reductase |
TxNIP |
Glutathione S-transferase π |
Glutathione S-transferase θ |
Catalase |
Manganese superoxide |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low (%) | High (%) | P-value | Low (%) | High (%) | P-value | Low (%) | High (%) | P-value | Low (%) | High (%) | P-value | Low (%) | High (%) | P-value | Low (%) | High (%) | P-value | Low (%) | High (%) | P-value | |
| Age (years) | |||||||||||||||||||||
| ≤40 | 10 (71) | 4 (29) | 0.217 | 7 (47) | 8 (53) | 0.393 | 6 (38) | 10 (62) | 0.352 | 7 (54) | 6 (46) | 0.747 | 8 (67) | 4 (33) | 0.284 | 9 (60) | 6 (40) | 0.790 | 7 (47) | 8 (53) | 0.840 |
| 41–60 | 20 (47) | 23 (53) | 24 (56) | 19 (44) | 33 (58) | 24 (42) | 19 (46) | 22 (54) | 17 (43) | 23 (57) | 20 (50) | 20 (50) | 22 (54) | 19 (46) | |||||||
| >60 | 6 (43) | 8 (57) | 10 (71) | 4 (29) | 9 (53) | 8 (47) | 8 (57) | 6 (43) | 8 (57) | 6 (43) | 7 (50) | 7 (50) | 6 (46) | 7 (54) | |||||||
| Total | 36 | 35 | 41 | 31 | 48 | 42 | 34 | 34 | 33 | 33 | 36 | 33 | 35 | 34 | |||||||
| Histology | |||||||||||||||||||||
| Ductal NST | 35 (53) | 31 (47) | 0.170* | 38 (57) | 29 (43) | 0.632* | 43 (52) | 40 (48) | 0.276* | 33 (52) | 30 (48) | 0.178* | 30 (48) | 32 (52) | 0.307* | 34 (53) | 30 (47) | 0.458* | 33 (52) | 31 (48) | 0.486* |
| Lobular | 1 (20) | 4 (80) | 3 (60) | 2 (40) | 5 (71) | 2 (29) | 1 (20) | 4 (80) | 3 (75) | 1 (25) | 2 (40) | 3 (60) | 2 (40) | 3 (60) | |||||||
| Total | 36 | 35 | 41 | 31 | 34 | 34 | 33 | 33 | 36 | 33 | 35 | 34 | |||||||||
| TNM stage | |||||||||||||||||||||
| 2 | 4 (50) | 4 (50) | 0.593* | 3 (33) | 6 (67) | 0.135* | 6 (40) | 9 (60) | 0.293 | 5 (63) | 3 (37) | 0.337* | 3 (43) | 4 (57) | 0.537* | 5 (63) | 3 (37) | 0.408* | 5 (63) | 3 (37) | 0.372* |
| 3 | 31 (53) | 28 (47) | 35 (59) | 24 (41) | 39 (55) | 32 (45) | 27 (47) | 30 (53) | 27 (49) | 28 (51) | 29 (51) | 28 (49) | 28 (49) | 29 (51) | |||||||
| Total | 35 | 32 | 38 | 30 | 45 | 41 | 32 | 33 | 30 | 32 | 34 | 31 | 33 | 32 | |||||||
| ER status | |||||||||||||||||||||
| Negative | 18 (49) | 19 (51) | 0.718 | 20 (53) | 18 (47) | 0.435 | 23 (52) | 21 (48) | 0.844 | 16 (46) | 19 (54) | 0.467 | 15 (43) | 20 (57) | 0.218 | 21 (60) | 14 (40) | 0.187 | 15 (43) | 20 (57) | 0.185 |
| Positive | 18 (53) | 16 (47) | 21 (62) | 13 (38) | 25 (54) | 21 (46) | 18 (55) | 15 (45) | 18 (58) | 13 (42) | 15 (44) | 19 (66) | 20 (59) | 14 (41) | |||||||
| Total | 36 | 35 | 41 | 31 | 48 | 42 | 34 | 34 | 33 | 33 | 36 | 33 | 35 | 34 | |||||||
| PgR status | |||||||||||||||||||||
| Negative | 20 (54) | 17 (46) | 0.329 | 21 (55) | 17 (45) | 0.464 | 25 (56) | 20 (44) | 0.066 | 17 (49) | 18 (51) | 0.916 | 16 (47) | 18 (53) | 0.316 | 25 (69) | 11 (31) | 0.198 | 18 (50) | 18 (50) | 0.862 |
| Positive | 9 (41) | 13 (59) | 10 (45) | 12 (55) | 11 (34) | 21 (66) | 11 (50) | 11 (50) | 7 (33) | 14 (67) | 11 (52) | 10 (48) | 11 (52) | 10 (48) | |||||||
| Total | 29 | 30 | 31 | 29 | 36 | 41 | 28 | 29 | 23 | 32 | 36 | 21 | 29 | 28 | |||||||
| HER status | |||||||||||||||||||||
| Negative | 17 (43) | 23 (57) | 0.458 | 20 (48) | 22 (52) | 0.174 | 29 (52) | 27 (48) | 0.635 | 18 (45) | 22 (55) | 0.107 | 15 (38) | 24 (62) | 0.116 | 24 (60) | 16 (40) | 0.677 | 21 (54) | 18 (46) | 0.647 |
| Positive | 12 (52) | 11 (48) | 15 (65) | 8 (35) | 12 (46) | 14 (54) | 14 (67) | 7 (33) | 12 (60) | 8 (40) | 12 (55) | 10 (45) | 11 (48) | 12 (52) | |||||||
| Total | 29 | 34 | 35 | 30 | 41 | 41 | 32 | 29 | 27 | 32 | 36 | 26 | 32 | 30 | |||||||
| Pathological complete response | |||||||||||||||||||||
| CR | 7 (54) | 6 (46) | 0.802 | 7 (50) | 7 (50) | 0.559 | 7 (44) | 9 (56) | 0.397 | 3 (25) | 9 (75) | 0.050* | 6 (46) | 7 (54) | 0.757 | 10 (77) | 3 (23) | 0.045* | 8 (62) | 5 (38) | 0.387 |
| Non-CR | 29 (50) | 29 (50) | 34 (59) | 24 (41) | 41 (55) | 33 (45) | 31 (55) | 25 (45) | 27 (51) | 26 (49) | 26 (46) | 30 (54) | 27 (48) | 29 (52) | |||||||
| Total | 36 | 35 | 41 | 31 | 48 | 42 | 34 | 34 | 33 | 33 | 36 | 33 | 35 | 34 | |||||||
| Clinical complete response | |||||||||||||||||||||
| CR | 15 (56) | 12 (44) | 0.522 | 14 (50) | 14 (50) | 0.342 | 13 (43) | 17 (57) | 0.202 | 16 (64) | 9 (36) | 0.078 | 15 (60) | 10 (40) | 0.205 | 16 (59) | 11 (41) | 0.345 | 16 (59) | 11 (41) | 0.256 |
| Non-CR | 21 (48) | 23 (52) | 27 (61) | 17 (39) | 34 (58) | 25 (42) | 18 (42) | 25 (58) | 18 (44) | 23 (56) | 20 (48) | 22 (52) | 19 (45) | 23 (55) | |||||||
| Total | 36 | 35 | 41 | 31 | 47 | 42 | 34 | 34 | 33 | 33 | 36 | 33 | 35 | 34 | |||||||
Pearson's χ2 test of association values stated unless the frequency of observations in a cell was <5; therefore, Fisher's exact stated (indicated by *). Statistically significant P-values are indicated by bold font.